Health CarePharmaceuticals & Biotechnology
  • Price (USD)3.86
  • Today's Change-0.05 / -1.28%
  • Shares traded2.39m
  • 1 Year change-38.92%
  • Beta1.6090
Data delayed at least 15 minutes, as of May 22 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

  • Revenue in USD (TTM)3.01bn
  • Net income in USD-190.39m
  • Incorporated2013
  • Employees3.17k
  • Location
    Endo International PLCMinerva House, Simmonscourt RoadDUBLIN 000 00IrelandIRL
  • Phone+353 12682000
  • Websitehttp://www.endo.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Omeros Corporation113.56m-89.17m836.74m258.00------7.37-1.74-1.742.23-2.421.031.034.67440,162.80-81.26-101.03-152.41-150.8299.1298.12-78.52-155.401.46-2.955.20--274.33190.6533.35--64.18--
BioCryst Pharmaceuticals, Inc.47.77m-115.44m840.68m140.00--230.36--17.60-0.9453-0.94530.37740.02370.3425--8.98341,221.40-82.78-53.95-192.56-104.6094.3893.58-241.66-220.99---25.610.9565--136.4529.12-7.55--26.47--
ORIC Pharmaceuticals Inc-100.00bn-100.00bn843.27m57.00--------------2.66----------------------------0.00-------25.84------
Cue Biopharma Inc3.99m-38.25m855.61m45.00--17.68--214.53-1.62-1.620.16971.700.0754----88,629.55-72.28---91.97-------959.00------0.00--202.67--5.85------
Amphastar Pharmaceuticals Inc327.26m52.02m856.52m2.03k17.762.2712.082.621.041.046.718.150.58572.035.81161,448.009.342.2312.562.7442.1237.4615.953.701.67--0.10160.009.408.90952.89--17.35--
Atara Biotherapeutics Inc0.00-298.23m873.08m409.00--3.45-----5.47-5.470.004.290.00----0.00-95.54-54.63-105.09-59.06------------0.00-------26.13--162.50--
Endo International PLC3.01bn-190.39m886.66m3.17k----2.210.2942-0.8593-1.2313.21-3.230.31554.775.88950,302.00-1.99-9.33-2.38-11.5548.0438.95-6.32-36.791.791.331.10---1.114.1362.29---5.65--
Rhythm Pharmaceuticals Inc0.00-145.92m887.13m70.00--3.50-----3.84-3.840.005.740.00----0.00-57.19-46.34-60.80-49.81------------0.00-------90.01------
ImmunoGen, Inc.86.97m-89.47m896.45m75.00------10.31-0.5817-0.58170.5681-0.02360.2793--24.811,159,653.00-28.73---37.61--76.15---102.87-----3.38----53.93--38.33------
Athenex Inc122.86m-107.95m907.67m574.00--5.31--7.39-1.40-1.401.582.090.47432.273.41214,036.60-42.09-63.58-54.81-81.1043.6033.57-88.74-186.412.37-20.710.2536--13.61142.34-5.37--151.04--
NextCure Inc27.37m-17.85m910.83m69.00--2.75--33.28-1.10-1.101.2112.060.112----396,637.70-7.30---7.59-------65.22------0.014-------47.98------
Kura Oncology Inc0.00-68.41m918.29m62.00--3.76-----1.56-1.560.004.480.00----0.00-34.54-37.56-37.04-40.74------------0.0356-------4.46------
OraSure Technologies, Inc.156.08m12.59m922.92m472.0073.573.1845.255.910.20210.20212.514.680.48472.595.92330,675.803.916.114.266.8259.3563.288.0610.407.62108.320.00640.00-14.937.75523.35--25.39--
Gossamer Bio Inc0.00-201.77m956.24m171.00--2.56-----3.30-3.300.004.940.00----0.00-45.47---48.39--------------0.0852-------22.68------
Cerus Corporation96.45m-68.92m970.81m254.00--8.64--10.07-0.4775-0.47750.66570.68560.4931.786.04379,724.40-35.23-49.05-46.16-66.4365.4755.42-71.45-104.593.47-15.520.2826--23.3020.83-23.76--33.51--
Data as of May 22 2020. Currency figures normalised to Endo International PLC's reporting currency: US Dollar USD

Institutional shareholders

58.46%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 202031.53m13.90%
The Vanguard Group, Inc.as of 13 Apr 202029.97m13.21%
Renaissance Technologies LLCas of 31 Mar 202015.67m6.91%
Miller Value Partners LLCas of 31 Mar 202013.08m5.77%
Glenview Capital Management LLCas of 31 Mar 20209.68m4.27%
Paulson & Co., Inc.as of 31 Mar 20209.63m4.24%
SSgA Funds Management, Inc.as of 31 Mar 20209.00m3.97%
Morgan Stanley & Co. LLCas of 31 Mar 20206.39m2.82%
JPMorgan Investment Management, Inc.as of 31 Mar 20203.93m1.73%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20203.72m1.64%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.